Cellectar's Cash Dwindles Amidst Reduced Burn, Going Concern Looms

TL;DR

**Cellectar's cash is running on fumes, and without a major capital infusion, this biotech is headed for a fire sale or worse.**

AI Summary

Cellectar Biosciences, Inc. reported a net loss of $12,051,940 for the six months ended June 30, 2025, a significant improvement from the $27,561,355 net loss in the prior-year period. This reduction was primarily driven by a substantial decrease in operating expenses, with research and development costs falling from $14,433,523 to $5,816,896 and general and administrative expenses decreasing from $11,271,673 to $6,621,624. The company's cash and cash equivalents declined sharply to $11,041,027 as of June 30, 2025, down from $23,288,607 at December 31, 2024. Despite a gain on valuation of warrants of $161,598, the company continues to face a going concern risk, with management stating that available liquidity of approximately $15 million may only fund operations beyond the second quarter of 2026. Cellectar plans to secure additional outside capital through equity/debt sales or strategic transactions and implement cost-saving measures to address this liquidity challenge.

Why It Matters

Cellectar's significant cash burn and explicit 'going concern' warning are critical for investors, signaling potential dilution or even bankruptcy if new funding isn't secured. The substantial reduction in R&D spending, while improving net loss, could indicate a slowdown in pipeline progress, impacting future revenue potential and competitive positioning against larger biopharmaceutical firms. Employees face job insecurity, and customers (future patients) might see delays in drug development. The broader market will watch how this small biotech navigates its financial challenges, setting a precedent for other cash-strapped emerging growth companies.

Risk Assessment

Risk Level: high — The company explicitly states 'These uncertainties raise substantial doubt about the Company's ability to continue as a going concern.' Cash and cash equivalents decreased from $23,288,607 at December 31, 2024, to $11,041,027 at June 30, 2025, and management projects only approximately $15 million in unrestricted cash to fund operations beyond Q2 2026.

Analyst Insight

Investors should avoid CLRB given the severe going concern risk and explicit warning from management. Current shareholders should consider exiting their positions, as significant dilution or even a wind-down of operations are stated possibilities if additional capital is not secured.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

$13,695,183

total Debt

$6,228,148

net Income

-$12,051,940

eps

-$7.66

gross Margin

N/A

cash Position

$11,041,027

revenue Growth

N/A

Key Numbers

• $11,041,027 — Cash and cash equivalents (as of June 30, 2025, down from $23,288,607 at Dec 31, 2024)
• $12,051,940 — Net loss (for the six months ended June 30, 2025, an improvement from $27,561,355 in prior year)
• $5,816,896 — Research and development expenses (for the six months ended June 30, 2025, down from $14,433,523 in prior year)
• $6,621,624 — General and administrative expenses (for the six months ended June 30, 2025, down from $11,271,673 in prior year)
• $259,394,000 — Accumulated deficit (as of June 30, 2025, indicating significant historical losses)
• $15,000,000 — Available liquidity (projected to fund operations only beyond Q2 2026)
• 3,192,040 — Shares of common stock outstanding (as of August 12, 2025)
• $7.66 — Net loss per share - basic (for the six months ended June 30, 2025, compared to $25.38 in prior year)

Key Players & Entities

• Cellectar Biosciences, Inc. (company) — registrant
• U.S. SECURITIES AND EXCHANGE COMMISSION (regulator) — filing oversight
• NASDAQ Capital Market (company) — stock exchange
• iopofosine I 131 (product) — product candidate
• CLR 121225 (product) — product candidate
• Phospholipid Drug Conjugates (product) — technology platform
• Delaware (location) — state of incorporation
• Florham Park, New Jersey (location) — principal executive offices

FAQ

Risk Factors

• Going Concern Risk and Liquidity Needs [high — financial]: The company has a significant accumulated deficit of $259,394,000 as of June 30, 2025, and reported a net loss of $12,051,940 for the six months ended June 30, 2025. Available liquidity of approximately $15 million is projected to fund operations only beyond the second quarter of 2026, necessitating the securement of additional capital through equity/debt sales or strategic transactions.
• Dependence on Future Financing [high — operational]: Cellectar's ability to continue as a going concern is contingent upon its success in raising additional capital. The company's current cash and cash equivalents of $11,041,027 as of June 30, 2025, are insufficient for long-term operations without new funding. Failure to secure this financing could lead to a cessation of operations.
• Significant Reduction in R&D Spending [medium — operational]: Research and development expenses decreased substantially from $14,433,523 for the six months ended June 30, 2024, to $5,816,896 for the same period in 2025. While this improved net loss, it indicates a potential slowdown in pipeline development and future product innovation.
• High General and Administrative Expenses [medium — operational]: Despite a reduction from $11,271,673 to $6,621,624 for the six months ended June 30, 2025, general and administrative expenses remain a significant cost. These costs, coupled with R&D, contribute to the company's overall net loss.
• Warrant Liability Fluctuation [low — financial]: The company experienced a gain on valuation of warrants of $161,598 for the six months ended June 30, 2025, a significant swing from a loss of $2,504,915 in the prior year period. Volatility in warrant valuations can impact reported earnings.

Industry Context

Cellectar Biosciences operates in the highly competitive biotechnology sector, focusing on developing targeted therapies for cancer. The industry is characterized by long development cycles, significant R&D investment, and high regulatory hurdles. Success often depends on clinical trial outcomes and securing substantial funding for further development and commercialization.

Regulatory Implications

As a biotechnology company, Cellectar is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, failure to meet regulatory standards, or changes in regulatory policy can significantly impact development timelines and market access. The company's financial condition also poses a risk to its ability to meet ongoing compliance requirements.

What Investors Should Do

1. Monitor future financing activities closely.
2. Evaluate the impact of reduced R&D spending.
3. Assess the timeline for achieving profitability.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reported cash and cash equivalents of $11,041,027 and a net loss of $12,051,940 for the six-month period, highlighting ongoing liquidity concerns.
• 2024-12-31: End of Fiscal Year 2024 — Reported cash and cash equivalents of $23,288,607, indicating a substantial decrease in liquidity by mid-2025.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total historical losses since the company's inception. (Indicates the company's long history of unprofitability, with a deficit of $259,394,000 as of June 30, 2025.)

Going concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. Auditors assess this risk. (Management explicitly states a going concern risk, as current liquidity may only fund operations beyond Q2 2026.)

Warrant liability

A financial instrument that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. Its value can fluctuate. (The valuation of warrants can impact other income/expense, as seen with the $161,598 gain in the current period.)

Mezzanine equity

A hybrid form of capital that blends debt and equity features, often used by companies to fund growth or acquisitions. It typically ranks below senior debt but above common equity. (Cellectar has $1,382,023 in Series D preferred stock classified as mezzanine equity, which has priority over common stockholders in certain scenarios.)

Year-Over-Year Comparison

Compared to the prior year, Cellectar Biosciences has significantly reduced its net loss for the six months ended June 30, 2025, to $12,051,940 from $27,561,355. This improvement is largely due to a substantial decrease in both research and development expenses (down from $14,433,523 to $5,816,896) and general and administrative expenses (down from $11,271,673 to $6,621,624). However, cash and cash equivalents have sharply declined from $23,288,607 at December 31, 2024, to $11,041,027 as of June 30, 2025, exacerbating the going concern risk.

Key Financial Figures

• $0.00001 — ch registered Common stock, par value $0.00001 CLRB NASDAQ Capital Market Indica
• $259,394,000 — an accumulated deficit of approximately $259,394,000 as of June 30, 2025, and incurred a net
• $12,052,000 — nd incurred a net loss of approximately $12,052,000 during the six months ended June 30, 20

Filing Documents

• clrb-20250630x10q.htm (10-Q) — 1240KB
• clrb-20250630xex31d1.htm (EX-31.1) — 12KB
• clrb-20250630xex31d2.htm (EX-31.2) — 11KB
• clrb-20250630xex32d1.htm (EX-32.1) — 9KB
• 0001410578-25-001778.txt ( ) — 5546KB
• clrb-20250630.xsd (EX-101.SCH) — 37KB
• clrb-20250630_cal.xml (EX-101.CAL) — 32KB
• clrb-20250630_def.xml (EX-101.DEF) — 184KB
• clrb-20250630_lab.xml (EX-101.LAB) — 296KB
• clrb-20250630_pre.xml (EX-101.PRE) — 267KB
• clrb-20250630x10q_htm.xml (XML) — 868KB

Forward-Looking Statements

Forward-Looking Statements 3

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 5 Item 1.

Financial Statements

Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 4.

Controls and Procedures

Controls and Procedures 33

OTHER INFORMATION

PART II. OTHER INFORMATION 36 Item 1.

Legal Proceedings

Legal Proceedings 36 Item 1A.

Risk Factors

Risk Factors 36 Item 6. Exhibits 38 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q of Cellectar Biosciences, Inc. (the "Company", "Cellectar", "we", "us", "our") contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. Examples of our forward-looking statements include: our current views with respect to our business strategy, business plan and research and development activities; the progress of our product development programs, including clinical testing and the timing of commencement and results thereof; our projected operating results, including research and development expenses; our ability to identify a strategic partner with the resources to develop iopofosine I 131 (also known as iopofosine or CLR 131) or otherwise continue the development or pursue other strategic options in connection with iopofosine ; our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise; our ability to initiate a Phase 1 imaging and dose escalation safety study for CLR 121225 (CLR 125) and obtain the necessarty additional funding for such study; our ability to initiate a Phase 1b dose finding study for CLR 125 and obtain the necessary additional funding for such study; our ability to continue development plans for our clinical and preclinical assets; our ability to continue development plans for our Phospholipid Drug Conjugates (PDC); our ability to advance our technologies into product candidates; our ability to maintain orphan drug designation in the U.S. for iopofosine as a therapeutic for the treatment of multiple myeloma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma and lymphoplasmacytic lymphoma//Waldenstrom macroglobulinemia, and the expected benefits of orphan drug status; any disruptions to our suppliers; our current view regarding general economic and market conditions, including our competiti

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements CELLECTAR BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, December 31, 2025 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 11,041,027 $ 23,288,607 Prepaid expenses and other current assets 1,576,579 961,665 Total current assets 12,617,606 24,250,272 Property, plant & equipment, net 647,549 757,121 Operating lease right-of-use asset 400,248 436,874 Other long-term assets 29,780 29,780 TOTAL ASSETS $ 13,695,183 $ 25,474,047 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) CURRENT LIABILITIES: Accounts payable and accrued liabilities $ 4,678,713 $ 7,585,340 Warrant liability 1,095,926 1,718,000 Lease liability, current 92,022 84,417 Total current liabilities 5,866,661 9,387,757 Lease liability, net of current portion 361,487 409,586 TOTAL LIABILITIES 6,228,148 9,797,343 COMMITMENTS AND CONTINGENCIES (Note 7) MEZZANINE EQUITY: Series D preferred stock, 111.11 shares authorized, issued and outstanding as of June 30, 2025 and December 31, 2024 1,382,023 1,382,023 STOCKHOLDERS' EQUITY (DEFICIT): Series E-2 preferred stock, 1,225 shares authorized; 35.60 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 520,778 520,778 Common stock, $ 0.00001 par value; 170,000,000 shares authorized; 1,812,040 and 1,535,996 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 18 15 Additional paid-in capital 264,958,619 261,116,351 Accumulated deficit ( 259,394,403 ) ( 247,342,463 ) Total stockholders' equity (deficit) 6,085,012 14,294,681 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 13,695,183 $ 25,474,047 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 Table of Contents CELLECTAR BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) T

View Full Filing

View this 10-Q filing on SEC EDGAR